Profound Medical (PROF) announced the launch of a TULSA program by Texas Prostate and Dallas Medical Center to meet the growing demand for advanced prostate treatment – without surgery. Under the program, Texas Prostate will perform TULSA procedures for men with prostate cancer and benign prostatic hyperplasia in Dallas Medical Center’s state-of-the-art MRI suite, significantly expanding Medicare patient access to the TULSA Procedure.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical’s Earnings Call: A Balanced Outlook
- Profound Medical to Participate in Lake Street’s BIG9 Conference
- Profound Medical Reports Q2 2025 Growth and New Innovations in Prostate Treatment
- Profound Medical reports Q2 EPS (52c), consensus (40c)
- Profound Medical (PRN) Q2 Earnings Cheat Sheet